But as of late March, STARA’s status was in doubt, as anticipated funding was withdrawn. If STARA isn’t run, Dr. Weinstein predicts that attempts to cut biologics from dual regimens will continue and likely expand, but with unknown implications for long-term safety that he believes can only be addressed in a prospective, randomized trial.
Dr. Weinstein said that he had no relevant disclosures. Dr. Matteson had no disclosures. Dr. Kremer has received research support and been a consultant to more than 10 drug companies. Dr. Kavanaugh has received research support from more than 10 drug companies.
On Twitter @mitchelzoler